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Abstract: Cardiovascular disease remains the leading global cause of death, and the number of
patients with coronary artery disease (CAD) and exhausted therapeutic options (i.e., percutaneous
coronary intervention (PCI), coronary artery bypass grafting (CABG) and medical treatment) is on
the rise. Therefore, the evaluation of new therapeutic approaches to offer an alternative treatment
strategy for these patients is necessary. A promising research field is the promotion of the coronary
collateral circulation, an arterio-arterial network able to prevent or reduce myocardial ischemia in
CAD. This review summarizes the basic principles of the human coronary collateral circulation, its
extracardiac anastomoses as well as the different therapeutic approaches, especially that of stimulating
the extracardiac collateral circulation via permanent occlusion of the internal mammary arteries.
Keywords: human coronary collateral circulation; extracardiac anastomoses; collateral flow index;
collateral artery growth in man; permanent internal mammary artery occlusion
1. Introduction
According to the American Heart Association, “cardiovascular disease is the leading global cause
of death”, accounting for more than 17.6 million deaths in 2016, a number that is expected to grow to
more than 23.6 million by 2030 [1] In the event of acute coronary syndrome, percutaneous coronary
intervention (PCI) has been shown to be beneficial on outcome [2]. The beneficial effect of PCI on the
course of chronic stable coronary artery disease (CAD) has, so far, not been proven yet [3]. A recently
published randomized controlled trial among patients with stable, single-vessel CAD, the so called
ORBITA trial (e.g., Objective Randomised Blinded Investigation With Optimal Medical Therapy of
Angioplasty in Stable Angina) [4], found that PCI of the stenotic lesion did not prolong exercise time
by more than the effect of a sham procedure during the short observation period of six weeks. The new
aspect of the ORBITA trial was a methodological one, that is, the use of a sham control group of
patients undergoing the invasive coronary procedure, but not the actual PCI. The importance of a sham
control group in interventional procedures is pivotal, especially in a population with a high level of
suffering [5,6]. After all, it is known that the placebo effect can cause significant clinical improvements
(e.g., an increased exercise duration of >90 s [7]). Coronary artery bypass grafting (CABG), on the other
hand, has been found superior to PCI with respect to all-cause or cardiovascular mortality [8].
The number of patients with incomplete revascularization as well as so-called “no-option”-patients
(i.e., patients without options for PCI or CABG still suffering from symptoms of CAD despite optimal
medical therapy) is on the rise. It is estimated, that 30,000–50,000 new patients are affected in continental
Europe per year [9] and Williams et al. reported a prevalence of 25.8% of incomplete revascularization
in patients with CAD [10]. Apart from the limited quality of life, these patients also have a higher
mortality at three years than patients with complete revascularization [10].
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Accordingly, new therapeutic approaches are required. Because of the known survival benefit
of patients with a well-developed coronary collateral circulation [11,12], interventions aiming at
the promotion of coronary collaterals are a promising strategy. Coronary collaterals represent
pre-existing inter-arterial anastomoses and as such are the natural counterpart of surgically created
bypasses. To this end, biochemical (e.g., intracoronary vascular-endothelial growth factor or
intravenous granulocyte-macrophage colony-stimulating factor) as well as biophysical (e.g., external
counterpulsation) approaches have been evaluated for the promotion of those collaterals.
The aim of this review is to describe basic principles of the coronary collateral circulation, its
extracardiac anastomoses as well as different therapeutic approaches, especially that of stimulating
extracardiac coronary supply via permanent occlusion of the internal mammary arteries.
2. Basic Principles of the Human Coronary Collateral Circulation
2.1. Coronary Collateral Circulation
The development of the cardiovascular system during embryogenesis occurs by vasculogenesis,
a process defined as “the de novo formation of blood vessels from endothelial precursor cells” [13].
Directed by the concentration of local messenger substance, endothelial precursor cells sprout out
and start forming a dense vascular network with multiple anastomoses. The density of this network
is at its peak in neonates and declines subsequently by physiological regression, a process called
pruning [14–16].
Nevertheless, it has been hypothesized early on and tested that the coronary anastomoses of the
neonate do not vanish completely but some collaterals rather recede in calibre. This concept has been
decisively advanced by the findings of the Scottish pathologist W.F. Fulton, who found “numerous
anastomoses in all normal hearts” by using a vascular overlay detecting technique with radiographic
contrast medium containing uniform particles sized 0.5–2.0 µm to visualize even small arteries [17].
Interestingly, with changing vascular pressure- and resistance conditions, it is possible to recruit
these receded arterial anastomoses. This process is often seen during the course of CAD with
development of a pressure gradient across a stenotic lesion, which itself induces augmented flow
in preformed arterial anastomoses and finally, structural augmentation of these collateral arteries
(arteriogenesis). Accordingly, the prevalence of functional coronary anastomoses depends on the
presence of CAD and is highest in chronic total coronary occlusions [16].
Coronary collaterals in patients without coronary atherosclerosis range in calibre between 10–200
µm; collateral arteries of patients with CAD are approximately four times bigger (100–800 µm) [17].
This observation is in accordance with an experimental rabbit model, where occlusion of the femoral
artery increased the lumen diameter of pre-existent arterioles four- to fivefold [18]. “At the same time,
the growth in structural size goes along with a decreasing number of collateral arteries, a process
called pruning. Pathophysiologically and in the sense of the Hagen Poiseuille law, pruning may be
interpreted as a way of effectively reducing vascular resistance to collateral flow” [13].
2.2. Extracardiac Coronary Supply
Apart from inter-coronary arterial anastomoses, the human coronary arterial circulation is
supplied by several extracardiac anastomoses, also called the non-coronary collateral myocardial blood
flow (NCCMBF) [19]. Hence, the heart receives additional blood from the arteries of surrounding
structures [20–24]. Most of the extracardiac anastomoses originate from arteries, which supply the
pericardium [21] and these arteries are typically located at the sites of pericardial reflections (e.g.,
the entry of the caval veins or the exit of the great arteries) [22]. Thus, a well-known extracardiac
anastomosis connects the right internal mammary artery (IMA, also called internal thoracic artery) to
the right coronary artery via the pericardiacophrenic branch and the sinus node artery [25] (Figure 1).
This extracardiac coronary supply can also develop after coronary bypass surgery as shown exemplary
in Figure 2 [22].
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Figure 1. Angiographic demonstration of extracardiac coronary supply. (A) Posterior-anterior 
projection of the right internal mammary artery (IMA, marked by *) and its connection to the right 
coronary artery via the pericardiacophrenic branch (marked by +). (B) Lateral projection using the 
same markers. Noteworthy, additional branches of the IMA (marked by #) heading towards the heart. 
 
Figure 2. Angiographic demonstration of extracardiac coronary supply after coronary artery bypass 
surgery. (A) Posterior-anterior projection of the left internal mammary artery bypass (marked by a *) 
on the left anterior descending coronary artery (LAD, marked by a #). Upstream of the bypass 
anastomosis, retrograde filling of the LAD is incomplete revealing coronary occlusion, which 
triggered the arteriogenesis of the pericardiacophrenic branch (marked by a +) (B) Lateral projection 
using the same markers revealing the connection of the pericardiacophrenic branch with the third 
diagonal branch (marked by III). 
Most commonly, NCCMBF originates from the bronchial or the internal mammary arteries [22]. 
Bjork et al. showed a prevalence for bronchial-coronary-anastomoses of more than 20% by reviewing 
200 coronary angiographies [26]. According to this observation, most of the anastomoses connect to 
the left circumflex artery (LCX) and demonstrate poor blood flow. However, blood flow within an 
Figure 1. Angiographic demonstration of extracardiac coronary supply. (A) Posterior-anterior projection
of the right internal mammary artery (IMA, marked by *) and its connection to the right coronary
artery via the pericardiacophrenic b nch (marked by +). (B) Later l projection using the same markers.
N t worthy, additional bra ches of the IMA (marked by #) h ading towards the heart.
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Figure 2. Angiographic demonstration of extracardiac coronary supply after coronary artery bypass
surgery. (A) Posterior-anterior projection of the left internal mammary artery bypass (marked by a
*) on the left anterior descending c ronary artery (LAD, m rked by a #). Upstre m of the ss
anastomosis, retrograde filling of the LAD is incomplete revealing coronary occlusion, which triggered
the arteriogenesis of the pericardiacophrenic branch (marked by a +) (B) Lateral projection using the
same arkers revealing the connection of the pericardiacophrenic branch with the third diagonal
branch (marked by III).
Most commonly, NCCMBF originates from the bronchial or the internal mammary arteries [22].
Bjork et al. showed a prevalence for bronchial-coronary-anastomoses of more than 20% by reviewing
200 coronary angiographies [26]. According to this observation, most of the anastomoses connect to
the left circumflex artery (LCX) and demonstrate poor blood flow. However, blood flow within an
anastomosis between two arterial beds depends on the respective vascular resistances. Thus, a constant
decrease of vascular resistance in one arterial bed causes an increased blood flow to it with associated
arteriogenesis. Consequently and depending on the underlying pathology, bronchial-to-coronary (e.g.,
Int. J. Mol. Sci. 2019, 20, 3726 4 of 20
in the case of a chronic occluded coronary artery [27]) as well as coronary-to-bronchial anastomoses
(e.g., during chronic pulmonary diseases [28]) have been described.
Additional evidence for extracardiac anastomoses comes from the work of Hudson et al., who, by
injecting ink into the coronary arteries, demonstrated anastomoses with anterior mediastinal, phrenic
and intercostal arteries as well as with esophageal arterial branches of the aorta [21].
NCCMBF has also been increasingly recognized by cardiac surgeons as they discovered that
anastomotic blood flow can dilute, and thus, be a potential hazard to cardioplegia [23]. To quantify
this phenomenon, several studies have been conducted with reported values of anastomotic perfusion
ranging between 3.4 to 14 mL/100 g/min [29,30] during cardiopulmonary bypass with cross-clamping
of the aorta.
2.3. Quantitative Evaluation of the Coronary Collateral Circulation
The first in vivo functional coronary collateral measurements were conducted in the 1970s,
showing a direct relation between “angiographic appearance and functional performance of coronary
collaterals during bypass surgery” [31]. Rentrop et al. proposed a transluminal coronary angioplasty
approach, which divided the appearance of coronary collaterals in four groups (0 = no collateral filling
from the contralateral vessel to 3 = “complete filling of the epicardial segment of the artery”) [32].
Unfortunately, the method is only qualitative and evaluation of extracardiac collaterals is not feasible.
Thereafter a method for quantitative coronary collateral function assessment based on coronary
occlusive pressure measurements was introduced. The so called collateral flow index (CFI) [33,34]
“is the ratio between mean coronary occlusive and aortic pressure both subtracted by central venous
pressure as obtained during a 1-min proximal coronary balloon occlusion” [33] (Figure 3). The method
is accepted as the reference method for functional collateral assessment in patients with chronic stable
CAD [35,36]. In terms of sufficient collateral blood supply, it has been demonstrated that a CFI of
>0.20–0.25 is related to absent signs of ischemia on the intracoronary electrocardiogram (i.c.ECG)
during this 1-min coronary artery balloon occlusion [37,38].
Int. J. Mol. Sci. 2019, 20, 3726 5 of 20
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Figure 3. Collateral flow index (CFI) measurement. (A) Simultaneous recordings of mean and phasic aortic (red signals, Pao), coronary occlusive (black signals, 
Poccl) and central venous pressure (blue signals, CVP) immediately before (left side) and during coronary artery occlusion in a patient with poorly functional 
collaterals. (B) Detection of myocardial ischemia during the coronary artery occlusion by the intracoronary electrocardiogram (i.c.ECG). Immediately after balloon 
occlusion, the i.c.ECG shows marked electrical alternations with flipped T-waves and ST-segment elevation (marked by the black square). Generally, a CFI of >0.20–
0.25 is related to absent signs of ischemia on i.c.ECG during a 1-min proximal coronary occlusion. 
Figure 3. Collateral flow index (CFI) measurement. (A) Simultaneous recordings of mean and phasic aortic (red signals, Pao), coronary occlusive (black signals, Poccl)
and central venous pressure (blue signals, CVP) immediately before (left side) and during coronary artery occlusion in a patient with poorly functional collaterals. (B)
Detection of myocardial ischemia during the coronary artery occlusion by the intracoronary electrocardiogram (i.c.ECG). Immediately after balloon occlusion, the
i.c.ECG shows marked electrical alternations with flipped T-waves and ST-segment elevation (marked by the black square). Generally, a CFI of >0.20–0.25 is related to
absent signs of ischemia on i.c.ECG during a 1-min proximal coronary occlusion.
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CFI has also been determined in patients with angiographically normal coronary arteries, revealing
functional collateral arteries “to the extent, that one fifth to one quarter of them (i.e., the patients without
coronary stenoses) do not show signs of myocardial ischemia during the brief vascular occlusions” [39].
Those findings of functional sufficient collaterals even in the absence of CAD support the above
mentioned pathoanatomic observations [17], that coronary anastomoses calibre remain functional to a
considerable degree.
3. Angiogenesis and Arteriogenesis
To understand the different therapeutic approaches for promoting the coronary collateral
circulation, it is crucial to differentiate between two basic physiologic principles, that is, angiogenesis
and arteriogenesis.
3.1. Angiogenesis
The formation of capillaries from pre-existing vessels to expand the microvascular system
by increasing the capillary density is called angiogenesis. Driven by several growth factors such
as hypoxia-inducible factor 1α, vascular endothelial growth factor (VEGF) [40] and inflammatory
mediators as well as inflammatory cells (mainly monocytes [41]), a local milieu is formed [42] which
promotes the proliferation and migration of endothelial cells, pericytes and smooth muscle cells.
Thereby, “the amplification of the vascular network occurs within a short time due to either abluminal
outgrowth (sprouting) or intraluminal division (intussusceptive growth) of capillaries” [43]. In contrast
to arteriogenesis, angiogenesis is mostly driven by metabolic demands (i.e., hypoxemia) [44]
3.2. Arteriogenesis
“Although capillary sprouting may deliver some relief to the underperfused territory, only true
collateral arteries are principally capable of providing large enough amounts of blood flow to the
ischemic area at risk for necrosis or loss of function.” [41] Hence, arteriogenesis is the process of outward
remodelling [44] (i.e., growth in diameter and length) of pre-existing anastomoses [45], resulting in an
increased flow capacity of the artery.
Fluid shear stress, “the product of spatial flow velocity changes during the cardiac cycle and
blood viscosity” [46] “is the primary and strongest arteriogenic stimulus” [47]. It leads to the
expression of nitric oxide (NO), VEGF and monocyte chemoattractant protein-1 (MCP-1), resulting in
the attraction and activation of monocytes [41,44,48–51]. Those inflammatory cells conduct the process
of arteriogenesis with induction of cell proliferation as well as preparation of the extracellular matrix
to enable cell migration [48].
Arteriogenesis is a common phenomenon that interventional cardiologists encounter on a daily
basis as it appears (e.g., in the course of hypertensive heart disease with concentric left ventricular
hypertrophy and augmented myocardial mass). Due to the direct and curvilinear relationship
between myocardial mass and coronary arterial cross-sectional area [52], structural remodelling (i.e.,
arteriogenesis of the epicardial coronary arteries) occurs, resulting in large vascular calibres and,
because of undirected growth, also affecting vascular length. Thus, this leads to the typical corkscrew
pattern that is seen in this condition (Figure 4A).
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Figure 4. Angiographic presentation of two different pathophysiological etiologies of arteriogenesis. (A)
Arteriogenesis in the course of hypertensive heart disease with concentric left ventricular hypertrophy.
Enlarged myocardial mass is the driving force behind this arterial growth. (B) Arteriogenesis solely
initiated by constant elevation of fluid shear stress. Iatrogenic drainage of the left anterior descending
artery (LAD) into the right ventricular cavity after myocardial biopsy significantly increased coronary
blood flow and consequently vascular size.
Importantly and in contrast to the previously outlined process of angiogenesis, myocardial ischemia
is unrelated to this process [53,54]. Arteriogenesis depends solely on physical pressure gradients
across pre-formed anastomoses between different arterial territories with consequent augmentation of
endothelial fluid shear stress [47,53,55]. Figure 4B illustrates this concept: After myocardial biopsy
with perforation of the LAD and consecutive drainage into the (low resistance) right ventricular cavity,
blood flow in the LAD increased due to the abrupt decrease in “vascular” resistance. As a consequence,
abunda t growth of the LAD, both in cross-sectio al area and lengt , could be observed [56].
4. Therapeutic Promotion of the Coronary Collateral Circulation
The following chapter summarizes the most promising therapeutic approaches of coronary
collateral promotion divided according to the basic concept of biochemical or biophysical methods.
4.1. Biochemical Concepts
In general, biochemical concepts are “prone to potentially harmful effects, since arteriogenesis
shares many common mechanisms with inflammatory diseases, such as atherosclerosis” [44].
Accordingly, Epstein et al. coined (biochemical) collateral promotion a “Janus Phenomenon”, that is,
“whatever intervention enhances collaterals increases atherogenesis and vice versa” [57].
With the rapid development of angiogenic growth factors and the growing understanding of
their mechanisms of action, multiple trials testing collateral growth promotion have been initiated.
Because of the known pivotal role of monocytes in orchestrating the different processes of angio- and
arteriogenesis [50], most of the projects focused on the activation or the recruitment of this cell line.
Growth factors most extensively studied have been granulocyte-macrophage colony-stimulating factor
(GM-CSF) [58–62], granulocyte colony-stimulating factor (G-CSF) [63–66] or monocyte chemoattractant
protein-1 (MCP-1) [41]. Besides, also different fibroblast growth factors (FGF) [67–69] and VEGF [70]
have been clinically tested. Altogether, this study showed that angiogenesis is less efficient than
arteriogenesis [71] for promoting bulk collateral blood flow, since it only promotes microvascular
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density. Consequently, clinical trials evaluating the effect of angiogenetic factors such as FGF or VEGF
have failed to demonstrate a therapeutic effect that exceeds the effect of placebo treatment [67,68,70].
Colony-stimulating factors, on the other hand, have been found to promote the formation of
large interconnecting arterioles (arteriogenesis), which are required for the salvage of myocardium
in the presence of occlusive CAD [58]. Buschmann et al. [61] found that a continuous infusion of
GM-CSF into the stump of the acutely occluded femoral artery of rabbits enhanced blood flow to
the hind limb five-fold. The mechanism of action in that study has been found to be the prolonged
survival of monocytes, “known to play a decisive role in arteriogenesis” [61]. In two small but
randomized and placebo-controlled clinical trials with 35 patients in total, GM-CSF has been shown to
be efficacious in a short-term subcutaneous administration protocol of two weeks [58,59]. Both studies
have demonstrated a significant increase in CFI (from 0.116 to 0.159; p = 0.028 respectively from 0.21 to
0.31; p < 0.05). Of note, this beneficial effect of GM-CSF in the promotion of coronary collateral growth
could not be transferred to the clinical setting of peripheral vascular disease, where it failed to improve
the walking time [60]. Further, one of the clinical trials using GM-CSF for arteriogenesis had to be
stopped prematurely for safety concerns in the context of two patients with acute coronary syndrome
in the treatment group [59].
G-CSF has been reported in meta-analyses to be safe in terms of major adverse cardiovascular
events (cardiovascular death, recurrent myocardial infarction and in-stent restenosis) and toleration of
the treatment injections [72–74]. These findings and promising animal test results [75] have led to a
randomized, placebo-controlled clinical trial in humans, in which subcutaneous G-CSF was shown to
increase CFI from 0.121 to 0.166 (p < 0.0001) when administered every other day for two weeks [63].
Despite the above meta-analyses, one study assessing the outcomes and risks of G-CSF in patients with
CAD has reported an increased frequency of adverse outcomes (i.e., acute coronary syndrome) [64].
In conclusion, despite the promising results of small clinical trials or animal models using
biochemical concepts to therapeutically promote the coronary collateral circulation, none of the
approaches evaluated so far could be successfully translated into clinical practice. Besides the above
mentioned limitations such as inefficient collateral formation (i.e., angiogenesis) or potentially harmful
propagation of atherogenesis (i.e., the “Janus Phenomenon” [57]), a number of additional unresolved
issues remains. These include questions relating to the dosage, the application route and the timing of
administration of growth factors [44]. Importantly, considering that “no-option” patients with extensive
CAD are the most likely candidates for coronary arteriogenesis, safety of any collateral-promoting
substance is crucial [59].
4.2. Biophysical Concepts
The biophysical concept of arteriogenesis is to increase tangential vascular shear stress in
preformed coronary anastomoses. One of the natural ways of increasing vascular shear stress is
physical exercise [76]. However, because of different comorbidities it is often not feasible for patients
with CAD to perform physical exercise training sufficiently. Thus, several other biophysical approaches
have been introduced and will be described subsequently.
4.2.1. Physical Exercise
The positive effects of physical exercise on the cardiovascular system have been known for a long
time [77]. For instance, it was concluded in 1958 by Morris and Crawford that physically active people
are less prone to develop stable CAD in comparison with sedentary people [78]. Physical exercise
has a positive effect on several cardiovascular aspects such as vascular remodelling, increase of the
maximal coronary blood flow (i.e., coronary flow reserve; CFR) as well as a decrease of coronary
artherogenesis [79,80].
Concerning the effect of training on coronary collateral function, Scheel et al. observed an
arteriogenetic effect of physical exercise in dogs with a constricted coronary artery whereas this effect
was not observed in dogs without coronary stenosis [81]. In the groups with artificial coronary occlusion,
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exercise stress doubled the collateral growth and hence, the coronary flow reserve when compared to
none exercised dogs. In humans, Zbinden et al. documented an increase of the quantitative parameter
CFI in a proof-of-concept study [82]. They evaluated CFI, CFR and other cardiac parameters before
and immediately after exercise training of a healthy marathon runner and demonstrated an increase of
CFI from 0.23 to 0.37. Two small, non-randomized clinical trials have supported the positive effect
of physical exercise on coronary collateral function, the increase in coronary cross-sectional area [83]
as well as dose-dependent relation between training and increase in CFI [84]. Those results are in
agreement with several other studies [80,85–89], which showed augmented perfusion by collateral
vessels in response to exercise training. Besides, there have been other clinical trials failing to show
a beneficial effect on the collateral circulation by exercise as assessed by angiographic imaging, but
not by functional measurements [90]. However, the authors mention the limited validity of the
angiographic approach and despite the negative outcome on coronary collateral formation, the exercise
group had a significant better clinical outcome concerning the frequency of cardiac symptoms and the
physical performance.
Recently, the first randomized clinical trial on the effect of physical exercise on coronary collateral
function has been published [91]. Möbius-Winkler et al. randomly assigned 60 patients to two training
groups (moderate- and high-intensity exercise with 10 h of training per week in each group) and one
control group (usual care with encouragement to perform regular physical activity according to current
recommendations). After four weeks, both exercise groups showed a significant increase in CFI (from
0.142 to 0.198, p = 0.005 respectively from 0.143 to 0.202, p = 0.004) without a statistically relevant
difference between the training modalities whereas CFI in the control group remained unchanged
(from 0.149 to 0.150, p = n.s.).
In conclusion, the positive effect of physical exercise on the human coronary collateral circulation
has been repeatedly demonstrated. However, there remain important questions concerning the type
and extent of physical exercise for optimal promotion as well as the implementation for patients with
limited physical possibilities.
4.2.2. External Counterpulsation (ECP)
“External counterpulsation therapy was first developed as a resuscitative tool to support the
failing heart and was based on the hemodynamic principles of the intra-aortic balloon pump”, which
is the augmentation of diastolic blood flow with consecutive improvement of coronary perfusion as
well as ventricular afterload reduction [92]. ECP uses three pairs of pneumatic cuffs wrapped around
each of the lower extremities. Those cuffs are sequentially inflated from distal to proximal triggered by
the ECG. Besides augmenting diastolic blood flow and reducing ventricular afterload, ECP increases
tangential endothelial shear stress triggering arteriogenesis. Used as a safe, effective and low-cost
second line treatment in refractory angina pectoris, ECP has been shown to be efficacious in reducing
CAD symptoms as well as improving exercise time [92–96]. Of note, the positive effect appears to
outlast the actual, conventional seven week period of treatment [97].
The effects of ECP on the coronary collateral circulation have been evaluated in two invasive
clinical trials. Buschmann et al. demonstrated in a non-randomized study a significant increase in
CFI. Other invasive parameters obtained in that study as the index of microvascular resistance (IMR)
or quantitative coronary angiography (QCA) remained unchanged and hence, the increase of CFI
reflected a “true” improvement of the myocardial blood flow [98]. These results have been confirmed in
a randomized, sham-controlled clinical trial with an increase in CFI from 0.125 to 0.174 at a four-week
follow-up exam (p = 0.006) in the experimental, but not in the placebo group (CFI changed from 0.129
to 0.111, p = 0.14) [46].
Recently, the principle of external counterpulsation has been individualized in order to alleviate
the side effects of ECP (i.e., the cumbersome procedure with high pressure levels), thus increasing its
acceptance. The so called individual shear rate therapy (ISRT) adjusts the used treatment pressures of
the pneumatic cuffs according to individually adapted intra-arterial shear rates to achieve the same
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effect with reduced pressure values [99]. The calculation is based on Doppler-flow parameters in the
common carotid artery at different treatment pressure values. Due to this procedure, the individually
calculated treatment pressure ranged between 160 to 220 mmHg instead of the regular treatment
pressure of 250 to 300 mmHg.
4.2.3. Coronary Sinus Reducer
The biophysical concept of the coronary sinus reducer is based on a perioperative approach
during heart surgery with artificially narrowed coronary sinus for augmented retro-perfusion [100].
The exact pathophysiologic principle for a beneficial effect remains unclear [101]. One proposed
mechanism assumes that the venous back pressure as applied in the coronary sinus is regionally
balanced in the venous, but not in the vascular bed upstream of the microcirculation [102]. Based on
the two regionally counteracting responses of the microcirculation during myocardial ischemia, that
is maximal vasodilatation and increased myocardial compressive forces (i.e., augmented ventricular
wall stress due to diminished myocardial thickness), regional imbalance in microvascular resistance
with higher resistance in the ischemic area arises. Thus, augmented venous back pressure is able to
reach the non-ischaemic microcirculation more easily than the ischaemic one, thereby increasing the
microcirculatory resistance in the non-ischaemic zone. This leads to a flow diversion of arterialised
blood to the ischaemic area at risk under the necessary condition of functional collateral connections
originating from the non-ischaemic area [102].
Due to advances in percutaneous coronary intervention, and at the same time, increasing number
of patients with refractory angina pectoris, several investigators have picked up this approach by using
balloon-expandable, hourglass-shaped devices to physically narrow the coronary sinus [103–105]. In a
first-in-man study, this device has demonstrated relief of angina pectoris in 12 out of 14 patients without
options for coronary revascularization [103]. Subsequently, Verheye et al. performed a randomized,
sham-controlled clinical trial in 104 patients, which confirmed the results of the first study [101].
They showed an improvement in Canadian Cardiovascular Society (CCS) score as well as quality of
life. Nevertheless, exercise time and mean change in the wall motion index as assessed by means of
dobutamine stress echocardiography remained unchanged [101]. Subsequently and to evaluate the role
of this device in future clinical practice, a post marketing study is currently enrolling selected patients
without revascularization options (called Reducer-I-study; NCT02710435). They plan to recruit over
400 patients and assess the clinical efficacy as well as the long-term outcome with follow-ups up to five
years after implantation [104].
4.2.4. Pharmacologic Biophysical Arteriogenesis
Ivabradine, a specific inhibitor of the If-channel mainly expressed in sinoatrial nodal cells [106],
specifically decreases the heart rate without affecting cardiac contractility, afterload or vasomotion as it
occurs with beta-blockers [107,108]. Based on the biophysical rationale of diastolic prolongation by
ivabradine with extension of diastolic vascular shear stress, a small randomized placebo-controlled trial
has demonstrated a significant increase in CFI by ivabradine (from 0.107 to 0.152, p = 0.0461) [109]. This
result is in accordance with several other trials, which have shown an arteriogenic effect on coronary
arteries by initiating bradycardia [110–112]). However, despite the promotion of coronary collateral
supply, ivabradine has not been shown to be efficacious with respect to cardiovascular outcomes
(composite of death from cardiovascular causes or nonfatal myocardial infarction) in patients with
stable CAD [106] in bigger randomized trials such as the BEAUTIFUL [113] and SIGNIFY trials [114].
5. Therapeutic Promotion of Extracardiac Coronary Supply
The anatomical connection between the IMAs and the coronary arteries via their most proximal
branch (i.e., the pericardiacophrenic artery departing at the first or second intercostal space) is well
documented [21,22,25] (Figures 1 and 2). Additionally, due to the connection of the IMAs with the iliac
external arteries via the superior and inferior epigastric arteries, collateral supply from the caudal side
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amounts to approximately two thirds of the flow during IMA patency [102]. This dual blood supply
along with the direct anatomical connection to the coronary circulation provided the rationale for the
IMA ligation method as a surgical treatment for angina pectoris. Using a small incision between the
second and third rib under local anesthesia, transthoracic surgical access and ligation of the IMAs
was first performed by D. Fieschi in 1939 (i.e., before the advent of modern cardiac surgery with
cardioplegia and heart-lung-bypass) [115]. Later on, the approach was tested by a series of trials carried
out in the late 1950s [116–122]. The primary end point of those clinical trials was angina pectoris
and, inconsistently, ECG signs of myocardial ischemia. Battezzati et al. [116], after identifying anew a
connection between both IMAs and the myocardium, reported consistent improvement in terms of
cardiac symptoms in a uncontrolled trial among 304 CAD patients in 1959. Notable, this improvement
was sustained during a follow-up of up to four years after the surgical intervention. In a further
uncontrolled trial among 50 CAD patients, Kitchell et al. [123] reported similarly favorable results with
symptomatic relief in 68% of the patients undergoing bilateral IMA ligation.
The following sham-controlled trials of bilateral IMA ligation in 35 CAD patients coined the phrase
“surgery as placebo” in the context of their negative results [124–126]. Although the introduction
of a sham-control study design in the context of surgical trials was seminal [127], the conclusion
drawn from the negative results of the IMA ligation trials at hand is questionable. In the trial by
Cobb et al. [125], angina pectoris relief was found in five of eight patients (63%) after IMA ligation
and in five of seven patients (71%) after IMA sham ligation. Dimond et al. [126] reported nine of 13
patients in the verum and five of five patients in the sham-operation group, respectively. Thus, the
abrupt stop of bilateral transthoracic IMA ligation was mainly caused by the advent of modern cardiac
surgery with bypass grafting rather than by the slim evidence against IMA ligation claimed by the
controlled trials. Especially because the soft study end point of angina pectoris would have required
patient numbers at one order of magnitude higher than those recruited for the sham-controlled IMA
ligation trials [125,126].
Because of the slim evidence against IMA ligation and the promising surgical results in terms
of symptomatic relief, this therapeutic concept was revived 75 years after the first attempt using
percutaneous interventional techniques. In the context of soft study endpoints, the first observational
interventional study on the function of coronary supply by the IMAs has predefined intracoronary ECG
(i.c.ECG) ST-segment elevation during coronary occlusion, not angina pectoris, as the first end point for
ischemia [128]. In this trial, myocardial ischemia has been induced twice with and without simultaneous
IMA occlusion by proximal coronary balloon occlusion in the process of CFI measurement. Further, to
eliminate the effect of coronary collateral recruitment or ischemic preconditioning occurring during the
second (but not the first) occlusion on the collateral circulation, CFI measurement with simultaneous
IMA occlusion was performed before the control measurement without IMA occlusion. Despite
this conservative study design, the approach showed a consistently reduced i.c.ECG ST-segment
elevation during ipsilateral IMA with RCA or LAD occlusion as an expression of reduced ischemia.
Further, CFI has been found higher in the presence versus the absence of IMA occlusion in 68% of the
measurements, and overall, this difference amounted to +0.025 compared with the absence of IMA
occlusion (p < 0.0001) [128]. However, contralateral IMA occlusion did not cause an effect indicating
the necessity of anatomic vicinity. In this trial, functional connection between the coronary arteries and
the IMAs was slightly less frequent in case of LAD with left IMA occlusion (25 of 30 measurements)
than in the case of RCA with right IMA occlusion (28 of 30 measurements).
Based on those functional findings, an anti-ischemic therapeutic approach consisting in distal
IMA occlusion by interventional techniques could be a promising therapeutic alternative to IMA
bypass grafting. In an open-label proof-of-concept study, Stoller et al. investigated a catheter-based
permanent IMA occlusion in the setting of the less frequently grafted right IMA among patients with
ischemia in the RCA territory [129]. In this study, 50 patients with chronic stable CAD underwent
permanent device occlusion of the distal right IMA. CFI of the RCA measured immediately before
and six weeks after the IMA-occlusion showed a consistent increase from 0.071 at baseline to 0.132
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(p < 0.0001). Further, this augmented coronary blood supply was reflected by the i.c.ECG as a direct
measure of myocardial physiology revealing a decreased ischemia during RCA occlusion from baseline
to follow-up examination (p = 0.0015). Figure 5 illustrates this increased collateral function along with
decreased myocardial ischemia during coronary occlusion as outlined by an absent ST-deprivation in
the ECG of the follow-up intervention.
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6. Conclusions
Based on the growing problem of patients with coronary artery disease and incomplete
revascularization, several promising therapeutic alternatives for myocardial revascularization have
been examined. Because of the known survival benefit of patients with a functional coronary collateral
circulation, its promotion is a promising concept. However, until now, none of the evaluated concept
could be implemented in daily clinical practice despite appealing results in clinical trials.
Biochemical concepts of angio- or arteriogenesis by growth factors seem to be prone to potentially
harmful effects, since arteriogenesis shares many common mechanisms with inflammatory diseases,
such as atherosclerosis. Thus, the risk benefit ratio is inappropriate and further research using growth
factors was discontinued.
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Biophysical concepts are based on increasing arteriogenesis via elevated tangential vascular
fluid shear stress. Physical exercise training or external counterpulsation have been documented to
positively affect clinical symptoms as well as coronary blood flow. The effect of both physical arteriogenic
procedures is, however, transient (i.e., vanishes after its termination) and the time-consuming procedure
of several hours per week limits the use to selected, highly motivated patients.
Alternative techniques such as coronary sinus reduction or promotion of extracardiac coronary
supply by permanent occlusion of the distal internal mammary artery are promising approaches, since
they have a permanent effect and ought to be efficacious in reducing myocardial ischemia to the effect
that it is clinically relevant. Both approaches are being currently studied in ongoing clinical trials
(NCT0271043 respectively NCT03710070) and the results of these investigations will clarify the clinical
potential of those new therapeutic methods.
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